
10x Genomics, Inc.
TXG
Updated: 23/09/2026, 23:33:19
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
No summaries found.
- Share price
- $75.62
- Market cap
- $9.60B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Serge Saxonov
- Employees
- 1,178
- IPO date
- 12/09/2019
- Beta
- 2.077
- Last dividend
- $0.00
- Day range
- $74.75 – $81.93
- 52-week range
- $11.16 – $82.68
- 1-day performance
- -6.29%
- 1-year performance
- 577.60%
- Current drawdown (1Y)
- -8.54%
- CIK
- 0001770787
- CUSIP
- 88025U109
- ISIN
- US88025U1097
- Created
- 07/12/2025, 14:50:39
- Last update
- 23/09/2026, 23:33:19
Track 10x Genomics, Inc. with an AI analyst
See which prediction-market events move TXG, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
Zacks Investment Research • STOCK • 10/06/2026, 16:07:04
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
PRNewsWire • STOCK • 09/06/2026, 11:00:00
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha • STOCK • 04/06/2026, 18:22:56
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
Fool - Investing News • STOCK • 01/06/2026, 04:03:09
10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 14/05/2026, 01:00:42
10x Genomics Q1 Earnings Call Highlights
MarketBeat • STOCK • 09/05/2026, 04:10:37
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
Zacks Investment Research • STOCK • 08/05/2026, 13:45:54
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 08/05/2026, 03:01:19
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 07/05/2026, 21:01:17
10x Genomics Stock Up on Atera Launch, Spatial Biology Scale Enhanced
Zacks Investment Research • STOCK • 20/04/2026, 12:21:07
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
PRNewsWire • STOCK • 19/04/2026, 00:00:00
10x Genomics: Undervalued Amid Consumables-Led Transition
Seeking Alpha • STOCK • 24/03/2026, 02:35:16